Menu
Back to User profile » Dr Lutz Frankenstein
Papers published by Dr Lutz Frankenstein:
Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation
Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Schweizer PA, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2016, 10:677-686
Published Date: 16 February 2016
Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation
Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2015, 9:1217-1224
Published Date: 24 February 2015
Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy
Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Klein B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2015, 9:93-102
Published Date: 17 December 2014
Conversion to generic cyclosporine A in stable chronic patients after heart transplantation
Kraeuter M, Helmschrott M, Erbel C, Gleissner CA, Frankenstein L, Schmack B, Ruhparwar A, Ehlermann P, Katus HA, Doesch AO
Drug Design, Development and Therapy 2013, 7:1421-1426
Published Date: 28 November 2013
Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study
Doesch AO, Mueller S, Erbel C, Gleissner CA, Frankenstein L, Hardt S, Ruhparwar A, Ehlermann P, Dengler T, Katus HA
Drug Design, Development and Therapy 2013, 7:1323-1328
Published Date: 5 November 2013
Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation
Doesch AO, Mueller S, Akyol C, Erbel C, Frankenstein L, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA
Drug Design, Development and Therapy 2013, 7:1253-1258
Published Date: 21 October 2013
Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation
Gueler I, Mueller S, Helmschrott M, Oeing CU, Erbel C, Frankenstein L, Gleissner C, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA, Doesch AO
Drug Design, Development and Therapy 2013, 7:297-303
Published Date: 8 April 2013
Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
Doesch AO, Repp J, Hofmann N, Erbel C, Frankenstein L, Gleissner CA, Schmidt C, Ruhparwar A, Zugck C, Schnitzler P, Ehlermann P, Dengler TJ, Katus HA
Drug Design, Development and Therapy 2012, 6:289-295
Published Date: 12 October 2012